First Trust Advisors LP Sells 58,194 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

First Trust Advisors LP reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 66.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,818 shares of the company's stock after selling 58,194 shares during the period. First Trust Advisors LP's holdings in Teva Pharmaceutical Industries were worth $657,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. FMR LLC raised its stake in shares of Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after buying an additional 4,418,961 shares during the last quarter. Lingotto Investment Management LLP grew its stake in shares of Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock valued at $599,320,000 after acquiring an additional 688,862 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 2.2% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock worth $573,822,000 after acquiring an additional 569,412 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Teva Pharmaceutical Industries by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock valued at $203,642,000 after purchasing an additional 489,041 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Bank of America upped their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $23.71.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded down $1.13 during trading hours on Friday, hitting $16.94. The stock had a trading volume of 19,072,081 shares, compared to its average volume of 10,028,635. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The stock's fifty day simple moving average is $15.18 and its 200 day simple moving average is $17.45. The firm has a market capitalization of $19.21 billion, a price-to-earnings ratio of -11.68, a PEG ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Teva Pharmaceutical Industries's revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.48 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.